IRIS
TIRIBELLI, Mario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.983
EU - Europa 2.346
AS - Asia 639
AF - Africa 9
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 5
Totale 12.989
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.937
UA - Ucraina 866
CN - Cina 375
DE - Germania 342
IT - Italia 283
FI - Finlandia 257
FR - Francia 170
IE - Irlanda 159
SE - Svezia 150
VN - Vietnam 111
TR - Turchia 98
CA - Canada 44
GB - Regno Unito 40
PL - Polonia 23
IN - India 14
IR - Iran 14
BE - Belgio 13
RU - Federazione Russa 13
TG - Togo 8
EU - Europa 7
HK - Hong Kong 7
ID - Indonesia 6
ES - Italia 5
JP - Giappone 5
KR - Corea 5
AU - Australia 4
BG - Bulgaria 4
CZ - Repubblica Ceca 4
NL - Olanda 4
AT - Austria 2
GR - Grecia 2
HU - Ungheria 2
RO - Romania 2
AE - Emirati Arabi Uniti 1
CH - Svizzera 1
EG - Egitto 1
GL - Groenlandia 1
IL - Israele 1
LI - Liechtenstein 1
LT - Lituania 1
MX - Messico 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
RS - Serbia 1
SG - Singapore 1
TW - Taiwan 1
Totale 12.989
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.487
Fairfield 1.407
Houston 904
Ann Arbor 880
Ashburn 597
Jacksonville 578
Seattle 577
Chandler 551
Wilmington 494
Cambridge 467
Dearborn 395
Princeton 181
Beijing 172
Dublin 157
Dong Ket 110
Udine 105
Izmir 98
San Diego 82
Ogden 53
Des Moines 45
Norwalk 37
Nanjing 32
Boardman 31
Ottawa 31
Hefei 28
New York 25
Phoenix 24
Warsaw 22
Kunming 21
Hangzhou 18
Trieste 17
Guangzhou 16
Redmond 16
Brussels 13
Duino-Aurisina 13
Helsinki 13
Los Angeles 10
Jinan 9
Milan 9
Simi Valley 9
Andover 8
Fuzhou 8
Lomé 8
Toronto 8
Zanjan 8
Nanchang 7
Hong Kong 6
Grafing 5
Hebei 5
Rome 5
Saint Petersburg 5
Shenyang 5
Tokyo 5
Washington 5
Florence 4
Frankfurt am Main 4
Ningbo 4
Sofia 4
Jakarta 3
Jinhua 3
Leawood 3
Maserada Sul Piave 3
Nanning 3
Prague 3
Redwood City 3
Rovigo 3
Sacramento 3
Venezia 3
Zhengzhou 3
Athens 2
Augusta 2
Baotou 2
Barletta 2
Boston 2
Brugnera 2
Budapest 2
Cavaso del Tomba 2
Dolo 2
Edinburgh 2
Harbin 2
Indiana 2
Jiaxing 2
London 2
Madrid 2
Malo 2
Mogliano Veneto 2
Monmouth Junction 2
Montreal 2
Muggia 2
Siena 2
Vienna 2
Wuhan 2
Zhoushan 2
Adelaide 1
Amsterdam 1
Aprilia 1
Ardabil 1
Atlanta 1
Bangalore 1
Belgrade 1
Totale 9.926
Salva come PNG Salva come JPEG
Nome #
BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients 171
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. 151
Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. 142
Functional regulation of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology 135
Abdominal abscess and Hafnia alvei septicemia occurring during the aplastic phase after autologous stem-cell transplantation in a patient with diffuse large B-cell lymphoma. 134
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients 128
Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors 127
Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib 126
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years 126
Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients. 124
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival. 123
Histone post-translational modifications associated to BAALC expression in leukemic cells. 119
Clinical feature and outcome in seven patients wuth hyaline or mixed variant of Castleman’s disease. A single centre experience 117
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 117
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 116
ABCG2, Cytogenetics, and Age Predict Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission 112
Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells 112
Differences among young adults, adults and elderly chronic myeloid leukemia patients. 108
Imatinib mesylate (Glivec) pre-treatment does not have a negative effect on outcome of allogenic hematopoietic stem cell transplantation in Philadelphia-positive leukemias 107
Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. 107
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib 105
Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia 105
Nocardiosis with favourable clinical outcome in progressive B-chronic lymphocytic leukaemia 104
ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia 104
EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia. 103
ABCG2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome 103
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment 103
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 103
Long-term efficacy and safety of nilotinib therapy after imatinib failure in eosinophilic myeloproliferative neoplasm and ETV6-ABL rearrangement 102
Impact of fludarabine-based induction therapy on outcome of FLT3-/NPM1+ cytogenetically normal acute myeloid leukemia. 102
Evaluation of residual CD34+ Ph+ progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy 102
Brain natriuretic peptide level as marker of cardiac function in imatinib--treated chronic myeloid leukemia patients: no evidence of cardiotoxicity of imatinib therapy. 101
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 101
Unexpected phenotype of a typical NPM1 mutant 100
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia 100
High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients 100
Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis 100
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia 99
Clinical factors predictive of myelofibrotic evolution in patients with polycythemia vera. 99
The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia. 99
A phase II study of α-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia 99
Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia. 99
Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy 98
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 98
Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cells 97
The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype 97
All-trans retinoic acid (ATRA) potentiates the in vitro inhibitory effects of IFN-alpha in parental (32D) and p210-bcr/abl transfected (LG7) murine myeloid cell lines 96
Donor compatibility and performance status affect outcome of allogeneic haematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukaemia 96
Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib 96
Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib? 96
Erratum: Functional regulation of the Apurinic/apyrimidinic endonuclease APE1 by Nucleophosmin (NPM1): Impact on tumor biology 95
Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era. 95
ABCG2 and CD200 define patients at high risk of relapse in ELN favorable subgroup of AML 95
How could patient reported outcomes improve patient management in chronic myeloid leukemia? 94
Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety data 93
The Sorafenib plus Nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of the FLT3 and p53 status. 93
Factors affecting outcome of allogeneic stem cell transplantation as salvage in patients with acute myeloid leukemia primary refractory to intensive induction therapy. 93
Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy 93
Intensified full-dose induction therapy (HD-MACHOP+radiotherapy) follwed dy consolidation with BAVC regimen and autologous stem cell transplantation as fron-line therapeutic approach for high risk aggressive non Hodgkin lymphoma 92
Q141K polymorphism of ABCG2 protein is associated with poor prognosis in adult acute myeloid leukemia treated with idarubicin-based chemotherapy. 92
Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL) 92
Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia. 92
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 91
Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicinee—Results from the Italian ‘Back to Life’ project 90
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series 89
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients 89
Differential gene expression induction by TRAIL in B chronic lymphocytic leukemia (B-CLL) cells showing high versus low levels of Zap-70 88
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 88
CONCOMITANT BCRP OVER-EXPRESSION AND FLT3-ITD MUTATION IDENTIFY A SUBSET OF ACUTE MYELOID LEUKEMIA PATIENTS AT HIGH RISK OF RELAPSE 87
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 years treated with induction regimens including fludarabine: retrospective analysis of 224 cases 86
5-AZACITIDINE FIVE DAYS/MONTHLY SCHEDULE IN SYMPTOMATIC LOW-RISK (IPSS: 0-1) MYELODISPLASTIC (MDS) PATIENTS. CLINICAL AND BIOLOGICAL EFFECTS Authors 86
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib 85
FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience 84
Endogenous endophthalmitis following disseminated fungemia due to Fusarium solani in a patient with acute myeloid leukemia 83
Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response. 82
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. 81
The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts 80
WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia 80
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. 80
EUTOS score predicts early optimal response to imatinib according to the revised 2013 ELN recommendations. 79
Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies. 79
Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy 79
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 78
Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy 77
Pilot study of combined therapy with interferon-alpha, arabinosyl cytosine and all-trans retinoic acid in patients with chronic myeloid leukemia in the chronic phase 76
Invasive fungal infections in allogneic haematopoietic stem cell transplantation: 12 years experience on 246 patients at a single institution 76
Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients 76
A simple Prognostic Scoring System for newly diagnosed acute leukaemia patients with normal karyotype: a retrospective analysis on 173 cases. 75
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 74
ABCB1 (PGP) and ABCG (BCRP) proteins are independent prognostic factors for complete remissione and relapse risk, respectively in normal karyotype adult de novo acute myeloid leukemia. 73
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 73
Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. 73
Reduced expression of cell cycle-associated genes in B lymphocytes purified from the peripheral blood of early-stage B chronic lymphocytic leukaemia patients. 72
Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study. 72
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia 72
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 72
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline 72
Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse 72
Daunoxome and ARA-C as reinduction chemotherapy in relapased acute lymphblastic leukemia. High complete remission rate despite multidrug resistance overexpression. 70
Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism. 70
Totale 9.637
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.728
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.728
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019874 0 0 0 0 0 0 0 0 0 0 537 337
2019/20204.204 245 198 177 603 325 650 496 479 354 334 77 266
2020/20212.255 40 275 61 307 92 298 111 240 306 85 232 208
2021/20221.348 64 145 51 65 23 66 78 60 16 226 325 229
2022/20231.338 199 80 8 156 136 391 6 108 170 24 43 17
2023/2024411 65 48 11 24 52 38 8 49 76 38 2 0
Totale 13.422